lenz therapeutics inc com - LENZ
LENZ
Close Chg Chg %
37.25 -0.91 -2.44%
Closed Market
36.34
-0.91 (2.44%)
Volume: 195.36K
Last Updated:
Nov 13, 2024, 4:00 PM EDT
Company Overview: lenz therapeutics inc com - LENZ
LENZ Key Data
| Open $37.35 | Day Range 35.93 - 38.93 |
| 52 Week Range 14.07 - 38.93 | Market Cap $1.02B |
| Shares Outstanding 27.50M | Public Float 22.35M |
| Beta 0.35 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$7.07 |
| Yield 0.00% | Dividend $1.03 |
| EX-DIVIDEND DATE Mar 22, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 178.60K |
LENZ Performance
| 1 Week | 6.22% | ||
| 1 Month | 50.75% | ||
| 3 Months | 63.74% | ||
| 1 Year | N/A | ||
| 5 Years | N/A |
LENZ Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About lenz therapeutics inc com - LENZ
LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Solana Beach, CA.
LENZ At a Glance
LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Solana Beach, California 92075
| Phone | 1-858-925-7000 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -124,651,000.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
LENZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.828 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.511 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.01 |
LENZ Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -20,775,166.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LENZ Liquidity
| Current Ratio | 39.196 |
| Quick Ratio | 39.196 |
| Cash Ratio | 38.745 |
LENZ Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -48.848 |
| Return on Equity | -51.952 |
| Return on Total Capital | -67.766 |
| Return on Invested Capital | -51.755 |
LENZ Capital Structure
| Total Debt to Total Equity | 0.197 |
| Total Debt to Total Capital | 0.197 |
| Total Debt to Total Assets | 0.192 |
| Long-Term Debt to Equity | 0.042 |
| Long-Term Debt to Total Capital | 0.042 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Lenz Therapeutics Inc Com - LENZ
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 121.00K | 734.00K | 8.35M | 2.41M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 121.00K | 734.00K | 8.35M | 2.41M | |
Depreciation
| 121.00K | 734.00K | 8.35M | 2.41M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +506.61% | +1,037.06% | -71.16% | |
Gross Income
| (121.00K) | (734.00K) | (8.35M) | (2.41M) | |
Gross Income Growth
| - | -506.61% | -1,037.06% | +71.16% | |
Gross Profit Margin
| - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 13.38M | 59.71M | 97.29M | 70.70M | |
Research & Development
| 9.12M | 37.93M | 64.44M | 29.73M | |
Other SG&A
| 4.26M | 21.78M | 32.85M | 40.97M | |
SGA Growth
| +46,034.48% | +346.29% | +62.95% | -27.33% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 54.83M | 10.32M | 62.08M | |
EBIT after Unusual Expense
| (68.33M) | (70.76M) | (105.64M) | (135.19M) | |
Non Operating Income/Expense
| - | - | 4.59M | 10.54M | - |
Non-Operating Interest Income
| - | - | 4.59M | 10.95M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 40.00K | - |
Interest Expense Growth
| - | - | -50.00% | -100.00% | - |
Gross Interest Expense
| - | - | - | 40.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (68.37M) | (70.76M) | (101.05M) | (124.65M) | |
Pretax Income Growth
| -62,627.52% | -3.49% | -42.81% | -23.35% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (68.37M) | (70.76M) | (101.05M) | (124.65M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (68.37M) | (70.76M) | (101.05M) | (124.65M) | |
Net Income Growth
| -62,627.52% | -3.49% | -42.81% | -23.35% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (68.37M) | (70.76M) | (101.05M) | (124.65M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (68.37M) | (70.76M) | (101.05M) | (124.65M) | |
EPS (Basic)
| -8.2407 | -8.5384 | -12.8908 | -15.304 | |
EPS (Basic) Growth
| -62,329.55% | -3.61% | -50.97% | -18.72% | |
Basic Shares Outstanding
| 8.30M | 8.29M | 7.84M | 8.15M | |
EPS (Diluted)
| -8.2407 | -8.5384 | -12.8908 | -15.304 | |
EPS (Diluted) Growth
| -62,329.55% | -3.61% | -50.97% | -18.72% | |
Diluted Shares Outstanding
| 8.30M | 8.29M | 7.84M | 8.15M | |
EBITDA
| (13.38M) | (59.71M) | (97.29M) | (70.70M) | |
EBITDA Growth
| -46,034.48% | -346.29% | -62.95% | +27.33% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 36.714 | |
| Number of Ratings | 7 | Current Quarters Estimate | -0.409 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -2.823 | |
| Last Quarter’s Earnings | -0.38 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -7.846 | Next Fiscal Year Estimate | -2.346 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 3 | 7 | 7 |
| Mean Estimate | -0.41 | -0.51 | -2.82 | -2.35 |
| High Estimates | -0.39 | -0.48 | -1.82 | -1.19 |
| Low Estimate | -0.45 | -0.57 | -4.76 | -3.12 |
| Coefficient of Variance | -5.81 | -10.19 | -46.54 | -26.20 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 1 | 1 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Lenz Therapeutics Inc Com - LENZ
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Lenz Therapeutics Inc Com - LENZ
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 16, 2024 | Daniel R. Chevallard Chief Financial Officer | 3,188 | Open market or private purchase of non-derivative security Non-derivative transaction at $15.68 per share | 49,987.84 |
| May 15, 2024 | James W. McCollum Director | 525,565 | Open market or private purchase of non-derivative security Non-derivative transaction at $15.99 per share | 8,403,784.35 |
| Apr 9, 2024 | James W. McCollum Director | 477,600 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | Frédéric Guerard Director | 27,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | Frédéric Guerard Director | 23,571 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | Frédéric Guerard Director | 30,897 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | Zach Scheiner Director | 27,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | Versant Venture Management LLC | 842,162 | Other acquisition or disposition | 0.00 |
| Apr 9, 2024 | Shelley B. Thunen Director | 27,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | James W. McCollum Director | 27,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | James W. McCollum Director | 6,575 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | James W. McCollum Director | 494,233 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $15.03 per share | 7,428,321.99 |
| Apr 9, 2024 | RA Capital Management LP Director | 2,386,301 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | RA Capital Management LP Director | 27,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | RA Capital Management LP Director | 5,371 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | RA Capital Management LP Director | 10,580 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | RA Capital Management LP Director | 54,582 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 9, 2024 | RA Capital Management LP Director | 694,755 | Open market or private purchase of non-derivative security Non-derivative transaction at $15.03 per share | 10,442,167.65 |
| Apr 9, 2024 | RA Capital Management LP Director | 3,319,339 | Open market or private purchase of non-derivative security Non-derivative transaction at $15.03 per share | 49,889,665.17 |
| Apr 9, 2024 | RA Capital Management LP Director | 164,729 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |